---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073909"
form_type: "8-K"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:18:51.325050+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Raphael Pharmaceutical ready to launch RaphaWell RA supplement in US after clinical trial

## Summary
- RaphaWell is a 100% natural, plant-based dietary supplement for rheumatoid arthritis symptom management.
- Completed proof-of-concept clinical trial under IRB approval; pain levels reduced from 75% negative to 50% at week 8.
- Morning stiffness improved from 75% participants at baseline to 41.67% at week 8.
- Company intends to engage a US manufacturer to scale production; product to be sold as standalone supplement.

## SEC filing metadata
- accession: 0001213900-25-073909
- form_type: 8-K
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390025073909/0001213900-25-073909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390025073909/ea0252574-8k_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073909
- JSON: https://secwatch.observer/filing/0001213900-25-073909.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.